GMAB

🏥 Healthcare

Genmab A/S

Conservative #9Aggressive #11Low Risk

$29.29+1.35%

Day High$29.48

Day Low$28.94

Volume2.1M

Mkt Cap$18.0B

52W Low $1752W High $35

Market Cap

$18.5B

P/E Ratio

13.1

Sector avg: 19.1

Rev Growth

22.8%

Sector avg: 8.0%

Earnings Growth

69.4%

Profit Margin

36.4%

Sector avg: 16.9%

Debt/Equity

0.03

Score Breakdown

Overall Score90.3

Fundamental Score84.5

ML Score97.9

Score by Horizon

3 Month

83.4

6 Month

93.2

Primary

1 Year

98.1

Quality Assessment

Earnings Grade

Strong fundamentals, high earnings quality

Position Sizing

Suggested Allocation

Confidence

high

Analysis Signals

Positive Signals

Fundamental: 84.5 (sector-relative)

ML percentile=97.9 (pre-ranked by batch)

Procyclicality dampener: ML weight reduced to 9.0% (S&P 500 return=25.0% > 20% (extended rally); Yield curve inverted (-10bp) — recession signal; Late-cycle score 2/3 → ML weight ×0.90)

Blend: 91% fund (84.5) + 9% ML (95.1) = 85.5

Market-cap adj: +2.0pt ($18.5B)

Risk Signals

Risk (low): Moderate vol 10.3% → +2.8pt

Sector Peer Comparison(Healthcare — 11 stocks in universe)

Stock	Score	P/E	Rev Growth	Margin	Mkt Cap
GMABGenmab A/S	90.3	13.1	22.8%	36.4%	$18.5B
EXELExelixis, Inc.	83.5	15.1	7.0%	33.7%	$11.7B
SNYSanofi	83.4	9.1	5.5%	18.2%	$113.6B
NBIXNeurocrine Biosciences, Inc.	81.1	26.5	21.4%	16.7%	$12.5B
GEHCGE HealthCare Technologies Inc.	80.5	17.7	4.8%	10.1%	$36.6B
ALKSAlkermes plc	80.0	16.5	-6.4%	23.9%	$5.5B
Sector Average	79.0	19.1	8.0%	16.9%	—

Why This Stock

HealthcareReasonable P/EStrong revenue growthHealthy profit marginHigh quality

Scores are generated by a multi-stage ML pipeline combining fundamental analysis, ensemble predictions, and structural risk signals. All data is for research purposes only and does not constitute financial advice. Past performance does not guarantee future results.